Double-effective chitosan scaffold-PLGA nanoparticle system for brain tumour therapy: in vitro study

References

• Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science, 2004;303:1818–22
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: Preparation, properties and possible application in drug delivery. Curr Drug Deliv, 2004;1(4):321–33
   PubMedGoogle Scholar
• Brannon PL, Blanchette, JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 2004;56(11):1649–59
   Google Scholar
• Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Rev, 2001;35:161–204
   PubMed Web of Science ®Google Scholar
• Casciato DA, Lowitz BB. 2009. Manual of clinical oncology, cancer chemotherapy agents. Philadelphia, PA: Lippincott, Williams & Wilkins
   Google Scholar
• Çatıker E, Gümüşderelioğlu M, Güner A. Degradation of PLA, PLGA homo- and copolymers in the presence of serum albumin: A spectroscopic investigation. Polym Int, 2000;49:728–34
   Web of Science ®Google Scholar
• Forough R. 2006. New frontiers in angiogenesis. Dordrecht, The Netherlands: Springer
   Google Scholar
• Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med, 2002;8:808–15
   PubMed Web of Science ®Google Scholar
• Gifford SM, Grummer MA, Pierre SA, Austin JL, Zheng J, Bird IM. Functional characterization of HUVEC-CS: Ca+2 signaling, ERK ½ activation, mitogenesis and vasodilator production. J Endocrinol, 2004;182:485–99
   PubMed Web of Science ®Google Scholar
• Gupte A, Çiftçi K. Formulation and characterization of paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres. Int J Pharm, 2004;276:93–106
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004;350:2335–42
   PubMed Web of Science ®Google Scholar
• Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar RMNV. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release, 2007;119:197–206
   PubMed Web of Science ®Google Scholar
• Jie W, Yubao L. Tissue engineering scaffold material of nano-apatite crystals and polyamide composite. Eur Polym J, 2004;40:509–15
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Lee JS, Jeong JR, Shin SC, Kim JC, Chang YH, Chang YM, Kim JD. Nanoparticles of magnetic ferric oxides encapsulated with poly(d,l lactide-co-glycolide) and their applications to magnetic resonance imaging contrast agent. J Magn Magn Mater, 2004;272:2432–3
   Web of Science ®Google Scholar
• Menei P, Venier MC, Gamelin E, Saint-Andre JP, Hayek G, Jadaud E, Fournier D, Mercier P, Guy G, Benoit JP. Local and sustained delivery of 5-FU from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study. Cancer, 1999;86(2):325–30
   PubMed Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, Kumar MNVR. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release, 2007;119:77–85
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan nanoparticles of 5-FU for ophthalmic delivery; characterization, in-vitro and in-vivo study. Chem Pharm Bull, 2011;59(2):272–8
   PubMed Web of Science ®Google Scholar
• Nair KL, Jagadeeshan S, Nair SA, Kumar GSV. Biological evaluation of 5-FU nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomedicine, 2011;6:1985–97
   Google Scholar
• Nègre-Aminou P, Van Vliet AK, Van Erck M, Van Thiel GCF, Van Leeuwen REW, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta, 1997;1345:259–68
   PubMed Web of Science ®Google Scholar
• Perego P, Boiardi A, Carenini N, De Cesare M, Dolfini E, Giardini R, Magnani I, Martignone S, Silvani A, Soranzo C, Zunino F. Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs. J Cancer Res Clin Oncol, 1994;120:585–92
   Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J, 2001;1:65–70
   PubMedGoogle Scholar
• Shah A, MacDonald W, Goldie J, Gudauskas G, Brisebols B. 5-FU infusion in advanced colorectal cancer: comparison of three dose schedules. Cancer Treat Rev, 1985;69:739–42
   Google Scholar
• Silva GA, Ducheyne P, Reis RL. Materials in particulate form for tissue engineering. 1. Basic concepts. J Tissue Eng Regen Med, 2007;1:4–24
   PubMed Web of Science ®Google Scholar
• Sklar CA. Childhood brain tumors. J Pediatr Endocrinol Metab, 2002;15:669–73
   PubMed Web of Science ®Google Scholar
• Stein GH. T98G: An anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol, 1979;99:43–54
   PubMed Web of Science ®Google Scholar
• Soran Z, Tığlı RS, Gümüşderelioğlu M. Chitosan scaffolds with BMP-6 loaded alginate microspheres for periodontal tissue engineering. J Microencapsul, 2012;29(8):770–80
   PubMed Web of Science ®Google Scholar
• Tığlı RS, Gümüşderelioğlu M. Evaluation of alginate-chitosan semi IPNs as cartilage scaffolds. J Mater Sci Mater Med, 2009;20:699–709
   PubMed Web of Science ®Google Scholar
• Tığlı RS, Karakeçili A, Gümüşderelioğlu M. In-vitro characterization of chitosan scaffolds: Influence of composition and deacetylation degree. J Mater Sci Mater Med, 2007;18:1665–74
   PubMedGoogle Scholar
• Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 2004;10:145–7
   PubMed Web of Science ®Google Scholar
• Zmora S, Glicklis R, Cohen S. Tailoring the pore architecture in 3-D alginate scaffolds by controlling the freezing regime during fabrication. Biomaterials, 2002;23:4087–94
   PubMed Web of Science ®Google Scholar